Exploring the Potential of Adjuvant CDK4/6 Inhibitors in Hormone Receptor-Positive Early Breast Cancer: A Consistent Approach for All.

Cancers (Basel) · 2025 · PMC11852482 · PMID 40002156

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In addition, a pooled analysis of the MONALEESA-2, -3, and -7 trials showed a trend towards the improved efficacy of subsequent therapies after first-line ribociclib plus endocrine therapy, suggesting a post-treatment effect of ribociclib [ 67 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.